Error-controlled non-additive interaction discovery in machine learning models. [PDF]
Chen W, Jiang Y, Noble WS, Lu YY.
europepmc +1 more source
Application of Non-additive Measures and Integrals for Analysis of the Importance of Party Positions for Voting [PDF]
Alexander Lepskiy, Vladimir Smolev
openalex +1 more source
Next‐generation proteomics improves lung cancer risk prediction
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj +4 more
wiley +1 more source
Individual Differences in Infants' Curiosity Are Linked to Cognitive Capacity in Early Childhood. [PDF]
de Boer ER +4 more
europepmc +1 more source
Fuzzy Measures and Fuzzy Integrals : Non-Additive set Functions and Integrals
Toshiaki Murofushi
openalex +2 more sources
Potential therapeutic targeting of BKCa channels in glioblastoma treatment
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak +4 more
wiley +1 more source
Some new quantitative randomized response models using optional and partial scrambling for sensitive data. [PDF]
Iqbal S, Hussain Z, Omer T.
europepmc +1 more source
Evaluating the additive diagnostic value of DidRen LaserTest: Correlating temporal and kinematic predictors and patient-reported outcome measures in acute-subacute non-specific neck pain [PDF]
Guillaume Hage +5 more
openalex +1 more source
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source

